Also known as Docetaxel, Taxotere is a chemotherapy drug designed to combat cancer. Manufactured by Sanofi-Aventis, this drug was approved by the FDA in 1996 and has been in circulation to combat a variety of cancers, though breast cancer is the most popular.
Taxotere is administered once every three weeks. This treatment has become preferable because it reduces the number of visits needed and is therefore considered a more convenient treatment option.
The FDA had approved Taxotere to treat:
According to breastcancer.org, there are 3 million women currently suffering from breast cancer in the U.S., with approximately 300,000 more diagnosed in 2016 alone. It’s been estimated that as many as 75% of those diagnosed have been treated with Taxotere.
Consider the following questions:
If you answered yes to two or more of these questions, contact Liz Dudley today for a consultation on your qualification for a lawsuit.
If you or a loved one were prescribed Taxotere to treat early stage, curable, breast cancer and experienced permanent hair loss as a result, you may be eligible to seek compensation. Many breast cancer patients in the U.S. have received Sanofi’s chemotherapy drug, Taxotere, as a part of their cancer treatment. However, many have experienced disfiguring and permanent hair loss or permanent alopecia, related to their use of Taxotere.
The national federal Taxotere litigation which is consolidated into a Multidistrict Litigation [“MDL”] involves Defendant Sanofi’s failure to adequately warn doctors, women and the FDA that Taxotere causes PERMANENT hair loss, not temporary like the other chemotherapy agents on the market. Various studies have documented that this permanent, disfiguring side effect, also known as alopecia, occurred in 9%-15% of breast cancer patients taking Taxotere. The hair loss ranges from patchy loss to total scalp loss of all hair. This permanently disfigures women who now are cancer-free. But because they were treated with Taxotere, versus Taxol which causes no permanent hair loss, they are now suffering the devastating ramifications of having to wear wigs, scarves. This injury has decreased women’s quality of life, impacted their body image, and led to depression and/or emotional distress.
According to lawsuits filed, Sanofi is being blamed for misleading the public, the FDA and healthcare providers about the long-term effects of Taxotere. They claimed that it was more effective than Taxol [the gold standard for early stage breast cancer treatment and which does NOT cause PERMANENT hair loss] and that the side effects were the same as Taxol – that hair would grow back after chemotherapy. However, many patients have been left permanently disfigured due to severe hair loss, and their doctors were puzzled as to why their hair did not grow back.
1996 – Taxotere is approved by the US FDA.
Late 1990s – Sanofi sponsored a study called GEICAM 9805. It was revealed that 9% of women in the trial suffered permanent alopecia
2006 – Dr. Scot Sedlacek at the Rocky Mountain Cancer Center completes a study, where he found 6% of women in the study suffered permanent alopecia
2012 – Klugel publishes a study in the Annals of Oncology, where 20 cancer patients received Taxotere. All 20 were found to have permanent alopecia by the end of the study.
2013 – The National Cancer Research Institute publishes a study where 10-15% of patients were found to have permanent alopecia
June 20, 2014 – FDA issues safety announcement for alcohol content within Taxotere
December 2015 – Cases of permanent alopecia reported
July 2016 – MDL sought against Sanofi – currently comprising 33 lawsuits in 16 federal courts – to the U.S. District Court for the Eastern District of Louisiana.
Although it is most often used on women fighting breast cancer, other types of cancer may be treated with Taxotere. Any patient exposed to this drug has an increased risk of persistent alopecia. Estimates demonstrate that over 75% of women who were treated with Taxotere were not warned of the significantly increased risk of suffering from permanent hair loss.
Hair loss is common when patients receive cancer treatment, but hair growth typically returns after treatment has ended. Permanent baldness is not a common side effect. The compensation available will be dependent on a variety of other factors. Consultation with a qualified and experienced attorney is critical in determining eligibility.
Additionally, your permanent alopecia can also lead to psychological damage, a loss of your enjoyment in life, additional medical expenses, and possible lost wages during this trying time. You can rest assured that Attorney Liz Dudley is ready to fight against deceptive pharmaceutical companies on your behalf for compensation of your Taxotere-related hair loss.
If you are dealing with the negative side effects of Taxotere use, we are here to help. There is no need for you to continue to suffer in silence. If you or a loved one have experienced any of these side effects, please call today for your free case review. Time to file a lawsuit may be limited, so contact us now to protect your rights.